Xolair Literature Review Dissertation Example | Topics and Well Written Essays - 4000 words

Xolair Literature Review - Dissertation Example The intensity, chemical properties, action mechanisms, and associated with omalizumab are all pre-generalized; however, they are controlled at the time of its manufacturing when done under the label of Xolair, and involve few specific dimensions to be identified. Further, understanding its production procedure in the raw-to-commercial forms contributes greatly towards building a theoretical relationship between its positive and negative impacts (â€Å"Xolair Fact Sheet†, 2011). Therefore, this review initiates by opening a succinct discussion regarding its origins and chemical features, which is followed by a detailed description of its production, purification, and commercialization phases. After this, some pros and cons associated with the drug are discussed, along with some secondary clinical trials that shed light on its efficacy in different age groups and dosage formulations. In the final sections of this review, a brief list of general precautions and pre-defined pharma cokinetic properties are also added to not to leave some important aspects untouched. Therefore, the reader of this review is suggested to make a close reading in order to explore relationship between different dimensions of Xolair. ... es a bond with receptors of patient’s cellular membrane and as a reaction produce inflammatory mediators from within (â€Å"Scientific Discussion-Zolair†, n.d.). In this type of reaction, an anti-lgE is supposed to restrict the creation of bond between lgE and cell membrane receptors, in order to reduce the release of inflammatory mediators (Miller et al., 2008). It happened in 1987 at Houston, Texas, that scientists of a local pharmaceutical firm (Tenox) carefully studied the phenomenon of asthma prevalence, and came up with a laboratory prototype of an anti-lgE, which until the year 1991 was unable to get international exposure. However, in the late 1990’s, controlled clinical trials were conducted over patients with mild and severe paediatric and allergic rhinitis by the collaboration of different international pharmaceutical firms, and from the year 1996, omalizumab was made available publicly under the trade name of Xolair by different pharmaceutical firms a s one of the most effective allergic asthma treatment drug, referred commonly as anti-lgE. However, despite several clinical trials and experiments over the commercial product of Xolair (and its composing omalizumab), there are still researches and developments which are being conducted in order to verify all the observable effects in different cases of asthma (â€Å"Tanox, Inc. – 2010 Company Profile†, 2010). 3. Drug Description: Xolair (or omalizumab) can be terminologically described as a monoclonal anti-body derived from recombinant chromosome (based over lG1k) which impasses particularly to mammal immunoglobulin E (or lgE). Further, its pharmacodynamics reveals that it constrains the association of lgE with cellular membrane receptors (specifically FC3Rl) over the surface of mast cells and basophils